ITEM 8.01 Other Events.
On December 30, 2008, GTx, Inc. issued a press release announcing the
submission of a New Drug Application with the U.S. Food and Drug Administration
(FDA) for toremifene 80 mg, an oral selective estrogen receptor modulator
(SERM), for the prevention of bone fractures in men with prostate cancer on
androgen deprivation therapy (ADT). A copy of the press release is furnished as
Exhibit 99.1 to this Current Report.
ITEM 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number Description
99.1 Press Release issued by GTx, Inc. dated December 30, 2008
|
Add
GTXI to Portfolio
Set Alert
Email to a
Friend